Keros Therapeutics, Inc. (KROS)
10.96
-0.16
(-1.44%)
USD |
NASDAQ |
Mar 20, 16:00
10.95
-0.01
(-0.09%)
After-Hours: 20:00
Keros Therapeutics Research and Development Expense (Quarterly) : 17.83M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 319.50M |
| Amicus Therapeutics, Inc. | 23.74M |
| MannKind Corp. | 27.59M |
| PTC Therapeutics, Inc. | 133.13M |
| Insmed, Inc. | 254.91M |